[{"NetIncomeLoss_1_Q2_USD":-60974000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":31502000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":15862000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":112163123.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":115377210.0,"CommitmentsAndContingencies_0_Q2_USD":null,"DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_0_Q2_USD":2500000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":1830000.0,"DeferredCompensationShareBasedArrangementsLiabilityCurrent_0_Q2_USD":2800000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-443978000.0,"Depreciation_2_Q2_USD":3781000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":595698000.0,"StockIssuedDuringPeriodValueNewIssues_0_Q2_USD":595700000.0,"PaymentsToAcquireInvestments_2_Q2_USD":642181000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":65000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":8178000.0,"AssetsCurrent_0_Q2_USD":909577000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":26715950.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":4780000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":4476000.0,"LeaseAndRentalExpense_2_Q2_USD":1060000.0,"SaleOfStockPricePerShare_0_Q2_USD":47.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":7927000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":220000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":685000.0,"CommonStockSharesIssued_0_Q2_shares":139233450.0,"Assets_0_Q2_USD":1258544000.0,"ShareBasedCompensation_2_Q2_USD":30985000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":42432000.0,"OperatingLeaseLiability_0_Q2_USD":53462000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q2_shares":12562263.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_2_Q2_USD":-1188000.0,"Liabilities_0_Q2_USD":95125000.0,"IncreaseDecreaseInOtherNoncurrentAssets_2_Q2_USD":-2458000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":89337000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":47296000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":90498000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2_Q2_USD":221633000.0,"LettersOfCreditOutstandingAmount_0_Q2_USD":4300000.0,"ProceedsFromStockPlans_2_Q2_USD":1438000.0,"OtherExpenses_2_Q2_USD":215000.0,"OtherExpenses_1_Q2_USD":156000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":5600000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":2340000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"InvestmentIncomeNetAmortizationOfDiscountAndPremium_2_Q2_USD":-20000.0,"CommonStockValue_0_Q2_USD":139000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q2_USD":210794000.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_2_Q2_USD":1419000.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1_Q2_USD":710000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":616761000.0,"TenantImprovements_0_Q2_USD":5000000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":1100000000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-114769000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-60754000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-503000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":151000.0,"OtherAssetsNoncurrent_0_Q2_USD":2160000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":280379000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":51067000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":1673026000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":4780000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":2846000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":34311000.0,"PaymentsForLeasingCostsCommissionsAndTenantImprovements_2_Q2_USD":2816000.0,"CommonStockSharesOutstanding_0_Q2_shares":139233450.0,"RestrictedCashNoncurrent_0_Q2_USD":4299000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":9253000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":2339000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-115454000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-60974000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":30985000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":16770000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-67530000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2_Q2_USD":4877000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":6813000.0,"LiabilitiesCurrent_0_Q2_USD":40895000.0,"AccountsPayableCurrent_0_Q2_USD":9057000.0,"SaleOfStockNumberOfSharesIssuedInTransaction_0_Q2_shares":13457447.0,"NonoperatingIncomeExpense_2_Q2_USD":5385000.0,"NonoperatingIncomeExpense_1_Q2_USD":2184000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":284678000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":9927000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":0.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.0835,"InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0_Q2_USD":4677000.0,"CashEquivalentsAtCarryingValue_0_Q2_USD":256773000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2_Q2_USD":1438000.0,"OperatingLeasePayments_2_Q2_USD":2800000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":8298000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":84605000.0,"NetIncomeLoss_2_Q2_USD":-115454000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":105253000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"LeaseCost_1_Q2_USD":2267000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-511576000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":8440000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-4116000.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"OperatingIncomeLoss_2_Q2_USD":-120839000.0,"OperatingIncomeLoss_1_Q2_USD":-63158000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":619271000.0,"SaleOfStockConsiderationReceivedOnTransaction_0_Q2_USD":632500000.0,"PreferredStockValue_0_Q2_USD":0.0,"DeferredIncomeTaxExpenseBenefit_2_Q2_USD":0.0,"OperatingLeaseCost_2_Q2_USD":3736000.0,"OperatingLeaseCost_1_Q2_USD":1868000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":1258544000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":30985000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":16770000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":93858000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":2395000.0,"OperatingExpenses_2_Q2_USD":120839000.0,"OperatingExpenses_1_Q2_USD":63158000.0,"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_2_Q2_USD":6829000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.03,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.53,"ProfitLoss_2_Q2_USD":-115454000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":3163000.0,"StockholdersEquity_0_Q2_USD":1163419000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":28307000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":1084564000.0,"VariableLeaseCost_2_Q2_USD":608000.0,"VariableLeaseCost_1_Q2_USD":399000.0,"LeaseCost_2_Q2_USD":4344000.0,"PurchaseCommitmentRemainingMinimumAmountCommitted_0_Q2_USD":5600000.0,"Ticker":"ALLO","CIK":"1737287","name":"ALLOGENE THERAPEUTICS, INC.","OfficialName":"Allogene Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1134878416.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20200805"}]